Dr. Maurizio Fava, Internationally Renowned Expert in the Field of Depression, Joins VistaGen's Clinical and Scientific Advisory Board Oct 7, 2015
Favorable Data on VistaGen Therapeutics' AV-101 for Major Depressive Disorder Published in Peer-reviewed Journal of Pharmacology and Experimental Therapeutics Sep 16, 2015
VistaGen Receives FDA and NIH Clearance to Initiate NIH-Funded Phase 2 Study of Orally Active AV-101 in Major Depressive Disorder Jul 1, 2015
VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder Feb 17, 2015
VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder Nov 17, 2014
VistaGen Receives Notice of Allowance for Canadian Patent Further Expanding Stem Cell Technology Platform Aug 19, 2014
VistaGen Receives Notice of Allowance for Canadian Patent Expanding Stem Cell Technology Platform Jun 16, 2014
